BioSpace News Archive

Q4 2020 Net Revenue $20.6 Million, Highest Net Revenue Quarter Since Launch of Jeuveau ® Pro Forma Cash Position of $57 Million at December 31, 2020 1

Evofem Biosciences, Inc. announced that it intends to offer and sell, subject to market and other conditions, $30 million of shares of its common stock in an underwritten public offering.

CooperCompanies announced that its Board of Directors elected Robert S. Weiss as Chairman of the Board and William A. Kozy as Vice Chairman and Lead Director. Both appointments are effective March 23, 2021.

Mettler-Toledo International Inc. (NYSE: MTD) today announced that it completed the acquisition of PendoTECH, a manufacturer and distributor of single-use sensors, transmitters, control systems and software for measuring, monitoring and data collection primarily in bioprocess applications.

Baxter International Inc. (NYSE:BAX), a leading global medical products company, will host a conference call to discuss its first-quarter 2021 financial results on Thursday, April 29, 2021 at 7:30 a.m. Central Time.

Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced financial results and recent corporate highlights for the full year ended December 31, 2020.

2020 marked a year of successful evolution to a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients -- Advancing selective chemoprotection via p53 biomarker strategy; 50% of all cancer patients across multiple tumor types have a p53 mutation Achieved clinical proof-of-concept in Phase 1b study of ALRN-6924 in p53-mutated small cell lung cancer (SCLC)

Seraph Research Institute (SRI) and Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that a 36-year old patient with recurrent glioblastoma achieved complete remission for a period of 15 months.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the Australian Therapeutic Goods Administration (TGA) has approved the use of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for people with cystic fibrosis (CF) ages 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene,

Certara, Inc., a global leader in biosimulation, announced the pricing of its underwritten public offering of 10 million shares of its common stock by certain existing stockholders at a price to the public of $25.00 per share.